Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation

ABSTRACT

Introduction

Nowadays, despite the wide availability of biological drugs and apremilast for psoriasis management, there is always a need for new therapies to customize the therapeutic approach on the basis of the patient’s clinical features and comorbidities, especially in order to achieve a prolonged therapeutic response. Thus, new treatment strategies are required to offer patients a personalized approach. In this scenario, major knowledge on psoriasis pathogenesis led to the development of deucravacitinib, an orally administered selective TYK2 inhibitor.

Areas covered

The aim of this manuscript is to review the current literature on the effectiveness and safety of deucravacitinib in psoriasis to offer readers a wide perspective. The current English literature was analyzed using the PubMed, Google Scholar, Embase, Cochrane Skin, and clinicaltrials.gov databases, selecting the most relevant manuscripts.

Expert opinion

Deucravacitinib appears to be an innovative weapon for the management of moderate to severe psoriasis. Despite its efficacy and safety profiles have been revealed by RCTs, real-life data are still scant. Certainly, deucravacitinib broadens the range of therapeutic alternatives for psoriasis patients, thus enhancing the holistic and personalized approaches required for the treatment of this disease.

KEYWORDS:

• Deucravacitinib
• psoriasis
• management
• treatments
• Biologics

Scientific accuracy review

Bristol Myers Squibb provided a scientific accuracy review at the request of the journal editor.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or mending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

L. Potestio: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. N Tommasino: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. G. Lauletta: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. F Feo: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. A. Ruggiero: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. F. Martora: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. A Portarapillo: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. L. Guerriero: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. M. Megna: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.